Article3 Biotech2025
Integrative network pharmacology and experimental validation of rutin-infused collagen-hydroxyapatite scaffold for promoting osteochondral regeneration.
Article in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanoemulsion-Mediated Suppression of Multidrug-Resistant Klebsiella pneumoniae via Oxygen Consumption Reduction and Biofilm Inhibition.Current microbiology · 2026Article
- Development and Evaluation of Scaffolds Based on Perch Collagen-Hydroxyapatite for Advanced Synthetic Bone Substitutes.Pharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteochondral defects (OCD), characterized by bone fractures and cartilage degradation, remain a significant health concern worldwide. This study reports on the development and evaluation of a bioactive scaffold composed of rutin, collagen, and hydroxyapatite (RUT-COL-HAP) for osteochondral tissue regeneration. Network pharmacology identified 51 common target genes of rutin related to chondrocyte and macrophage functions, with ten hub genes playing key roles in inflammation, ECM remodeling, and cell differentiation. Molecular docking revealed strong binding affinities between rutin and its targets. The structural and chemical properties of the scaffolds were assessed using SEM (scanning electron microscopy), FTIR (Fourier transform infrared spectroscopy), TGA (thermogravimetric analysis), and XRD (X-ray diffraction). The results confirmed the successful integration of all the components and demonstrated enhanced crystallinity, thermal stability, and a highly porous, interconnected architecture, particularly in the RUT5-COL-HAP variant. Porosity analysis showed an increase of 50% with higher rutin incorporation, while swelling and biodegradation assessments revealed that RUT5-COL-HAP maintained structural integrity and exhibited controlled degradation over 14 days. In vitro biocompatibility using MG-63 cells demonstrated over 120% cell viability at 72 h, and zebrafish embryo toxicity assays confirmed rutin's safety across all tested concentrations. Overall, the RUT5-COL-HAP scaffold demonstrated high porosity, favorable swelling behavior, and appropriate biodegradation rates. Structural analyses confirmed the ability of rutin to mimic the native extracellular matrix, and toxicity studies verified the safety of rutin for biomedical applications. Thus, it offers a promising biomaterial for osteochondral tissue engineering, providing an effective strategy for treating OCD and improving the clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.